Age (y/o) |
59.7 ± 14.6 |
50.8 ± 14.3 |
0.059 |
Male (n, %) |
18 (90.0%) |
14 (70.0%) |
0.235 |
Hypertension (n, %) |
3 (15.0%) |
3 (15.0%) |
1.000 |
Diabetes (n, %) |
2 (10.0%) |
1 (5.0%) |
1.000 |
Medication before ablation |
|
|
|
Beta blocker or CCB only (n, %) |
7 (35.0%) |
8 (40.0%) |
1.000 |
Class I AAD (n, %) |
8 (40.0%) |
5 (25.0%) |
0.501 |
Amiodarone (n, %) |
5 (25.0%) |
7 (35.0%) |
0.731 |
Presence of Sustained VT (n, %) |
9 (45.0%) |
3 (15.0%) |
0.082 |
Presence of Non-Sustained VT (n, %) |
5 (25.0%) |
4 (20.0%) |
1.000 |
PVC burden (pre-ablation) (beats/day) |
21267 ± 10968 |
19760 ± 14266 |
0.759 |
PVC burden (pre-ablation) (%)* |
19.5 ± 9.3 |
19.8 ± 14.3 |
0.948 |
Ejection fraction (pre-ablation) (%)* |
34.3 ± 7.3 |
40.7 ± 10.1 |
0.027 |
VA morphology |
|
|
|
RBBB morphology (n,%) |
10 (50.0%) |
9 (45.0%) |
1.000 |
Coupling interval |
522.0 ± 75.6 |
499.0 ± 55.3 |
0.278 |
QRSd, ms |
178.3 ± 23.1 |
149.0 ± 24.9 |
<0.001 |
IDT, ms |
64.7 ± 24.3 |
63.0 ± 19.9 |
0.815 |
PdW, ms |
57.4 ± 20.5 |
62.5 ± 20.5 |
0.432 |
Q-wave aVL/aVR ratio |
1.55 ± 0.43 |
1.44 ± 0.36 |
0.376 |
MDI |
0.44 ± 0.13 |
0.48 ± 0.12 |
0.271 |
Earliest activation before VA (ms) |
-41.2 ± 10.2 |
-40.5 ± 24.2 |
0.906 |
Successful ablation site (n, %) |
|
|
|
ASV |
5 (25.0%) |
6 (30.0%) |
1.000 |
Subvalvular |
6 (30.0%) |
2 (10.0%) |
0.235 |
GCV/AIV |
7 (35.0%) |
8 (40.0%) |
1.000 |
Epicardium |
2 (10.0%) |
4 (20.0%) |
0.661 |
Multiple site ablation requirement (n, %) |
14 (70.0%) |
8 (40.0%) |
0.111 |
AEAD |
16.3±8.6 |
16.3±7.9 |
0.985 |
Acute procedural success (n, %) |
18 (90.0%) |
17 (85.0%) |
1.000 |
PVC recurrence (n, %) |
10 (50.0%) |
3 (15.0%) |
0.041 |